Literature DB >> 16634746

Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.

J Eikenboom1, V Van Marion, H Putter, A Goodeve, F Rodeghiero, G Castaman, A B Federici, J Batlle, D Meyer, C Mazurier, J Goudemand, R Schneppenheim, U Budde, J Ingerslev, Z Vorlova, D Habart, L Holmberg, S Lethagen, J Pasi, F Hill, I Peake.   

Abstract

BACKGROUND: von Willebrand disease (VWD) type 1 is a congenital bleeding disorder caused by genetic defects in the von Willebrand factor (VWF) gene and characterized by a reduction of structurally normal VWF. The diagnosis of type 1 VWD is difficult because of clinical and laboratory variability. Furthermore, inconsistency of linkage between type 1 VWD and the VWF locus has been reported.
OBJECTIVES: To estimate the proportion of type 1 VWD that is linked to the VWF gene. PATIENTS AND METHODS: Type 1 VWD families and healthy control individuals were recruited. An extensive questionnaire on bleeding symptoms was completed and phenotypic tests were performed. Linkage between VWF gene haplotypes and the diagnosis of type 1 VWD, the plasma levels of VWF and the severity of bleeding symptoms was analyzed.
RESULTS: Segregation analysis in 143 families diagnosed with type 1 VWD fitted a model of autosomal dominant inheritance. Linkage analysis under heterogeneity resulted in a summed lod score of 23.2 with an estimated proportion of linkage of 0.70. After exclusion of families with abnormal multimer patterns the linkage proportion was 0.46. LOD scores and linkage proportions were higher in families with more severe phenotypes and with phenotypes suggestive of qualitative VWF defects. About 40% of the total variation of VWF antigen could be attributed to the VWF gene.
CONCLUSIONS: We conclude that the diagnosis of type 1 VWD is linked to the VWF gene in about 70% of families, however after exclusion of qualitative defects this is about 50%.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634746     DOI: 10.1111/j.1538-7836.2006.01823.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

1.  Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Authors:  V H Flood; J C Gill; P A Christopherson; J S Wren; K D Friedman; S L Haberichter; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.

Authors:  Daniel J Hampshire; George J Burghel; Jenny Goudemand; Laura C S Bouvet; Jeroen C J Eikenboom; Reinhard Schneppenheim; Ulrich Budde; Ian R Peake; Anne C Goodeve
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

3.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

4.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Authors:  Heidi L Lemmerhirt; Jordan A Shavit; Gallia G Levy; Suzanne M Cole; Jeffrey C Long; David Ginsburg
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

Review 5.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

6.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

7.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Brian R Branchford; Raymond G Hoffmann; Thomas C Abshire; Jorge A Di Paola; W Keith Hoots; Cindy Leissinger; Jeanne M Lusher; Margaret V Ragni; Amy D Shapiro; Robert R Montgomery
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

8.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

9.  Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice.

Authors:  Jordan A Shavit; Ani Manichaikul; Heidi L Lemmerhirt; Karl W Broman; David Ginsburg
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

10.  VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Authors:  Jeroen Eikenboom; Augusto B Federici; Richard J Dirven; Giancarlo Castaman; Francesco Rodeghiero; Ulrich Budde; Reinhard Schneppenheim; Javier Batlle; Maria Teresa Canciani; Jenny Goudemand; Ian Peake; Anne Goodeve
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.